Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1980 1
1984 1
1985 1
1986 1
1987 2
1989 2
1990 1
1993 6
1994 5
1995 2
1996 3
1997 2
1998 4
1999 4
2000 5
2001 8
2002 3
2003 3
2004 14
2005 12
2006 16
2007 11
2008 22
2009 21
2010 24
2011 31
2012 24
2013 36
2014 33
2015 42
2016 43
2017 53
2018 57
2019 52
2020 54
2021 30
Text availability
Article attribute
Article type
Publication date

Search Results

539 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for daily rocha
Search for Daisy Rocha instead (1 results)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Velazquez EJ, et al. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. N Engl J Med. 2019. PMID: 30415601 Clinical Trial.
After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged …
After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 …
Diaphragmatic mobility: relationship with lung function, respiratory muscle strength, dyspnea, and physical activity in daily life in patients with COPD.
Rocha FR, Brüggemann AK, Francisco DS, Medeiros CS, Rosal D, Paulin E. Rocha FR, et al. J Bras Pneumol. 2017 Jan-Feb;43(1):32-37. doi: 10.1590/S1806-37562016000000097. J Bras Pneumol. 2017. PMID: 28380186 Free PMC article.
OBJECTIVE: To evaluate diaphragmatic mobility in relation to lung function, respiratory muscle strength, dyspnea, and physical activity in daily life (PADL) in patients with COPD. METHODS: We included 25 patients with COPD, classified according to the Global Initiative for …
OBJECTIVE: To evaluate diaphragmatic mobility in relation to lung function, respiratory muscle strength, dyspnea, and physical activity in …
Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S, Bennett N, Mudd PN Jr, Frenkl TL. Mitcheson HD, et al. Eur Urol. 2019 Feb;75(2):274-282. doi: 10.1016/j.eururo.2018.10.006. Epub 2018 Oct 25. Eur Urol. 2019. PMID: 30661513 Clinical Trial.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Average daily micturitions at week 8 of part 1 (primary); urge incontinence episodes, total incontinence episodes, and urgency episodes (secondary). ...Results are limited by the relatively short treatment duration. CONCLUSION …
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Average daily micturitions at week 8 of part 1 (primary); urge incontinence episodes, …
Lactose intolerance: what is a correct management?
Santos GJ, Rocha R, Santana GO. Santos GJ, et al. Rev Assoc Med Bras (1992). 2019 Feb;65(2):270-275. doi: 10.1590/1806-9282.65.2.270. Rev Assoc Med Bras (1992). 2019. PMID: 30892454 Free article. Review.
Complete exclusion of conventional dairy products is not necessary since most individuals with LI can tolerate up to 12 grams of lactose daily in a single dose. Yogurts and cheeses matured for having low amounts of lactose are part of the strategy that allows consumption o …
Complete exclusion of conventional dairy products is not necessary since most individuals with LI can tolerate up to 12 grams of lactose …
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC. McInnes IB, et al. Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1. Arthritis Res Ther. 2019. PMID: 31375130 Free PMC article.
Therapeutic dose relevance of the in vitro analysis was assessed using calculated mean concentration-time profiles over 24 h obtained from JAKi-treated subjects. Time above IC(50) and average daily percent inhibition of pSTAT formation were calculated for each JAKi, cytoki …
Therapeutic dose relevance of the in vitro analysis was assessed using calculated mean concentration-time profiles over 24 h obtained from J …
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P. Rocha JF, et al. Eur J Clin Pharmacol. 2014 Sep;70(9):1059-71. doi: 10.1007/s00228-014-1701-2. Epub 2014 Jun 14. Eur J Clin Pharmacol. 2014. PMID: 24925090 Clinical Trial.
Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen s …
Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 1 …
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF; EVALUATE-HF Investigators. Desai AS, et al. JAMA. 2019 Sep 17;322(11):1077-1084. doi: 10.1001/jama.2019.12843. JAMA. 2019. PMID: 31475296 Free PMC article.
INTERVENTIONS: Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; target dosage, 10 mg twice daily) for 12 weeks. ...
INTERVENTIONS: Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; tar …
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators. Lees AJ, et al. JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703. JAMA Neurol. 2017. PMID: 28027332 Clinical Trial.
Fifty-one patients (11.9%) discontinued from the study during the double-blind phase. CONCLUSIONS AND RELEVANCE: Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in mean daily off-time in levodopa-treated patients with …
Fifty-one patients (11.9%) discontinued from the study during the double-blind phase. CONCLUSIONS AND RELEVANCE: Treatment with a 50-mg once …
COVID-19 epidemic in Brazil: Where are we at?
Lobo AP, Cardoso-Dos-Santos AC, Rocha MS, Pinheiro RS, Bremm JM, Macário EM, Oliveira WK, França GVA. Lobo AP, et al. Int J Infect Dis. 2020 Aug;97:382-385. doi: 10.1016/j.ijid.2020.06.044. Epub 2020 Jun 16. Int J Infect Dis. 2020. PMID: 32561425 Free PMC article.
In the last segment, from the 31(st) to the 63(rd) day, Brazil presented a daily percentage change (DPC) of 7.3% (95%CI= 7.2;7.5). For the country the average daily percentage change (ADPC) was 14.2% (95%CI: 13.8;14.5). ...
In the last segment, from the 31(st) to the 63(rd) day, Brazil presented a daily percentage change (DPC) of 7.3% (95%CI= 7.2;7.5). Fo …
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Ferreira JJ, et al. Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23. Lancet Neurol. 2016. PMID: 26725544 Clinical Trial.
BACKGROUND: Opicapone is a novel, once-daily, potent third-generation catechol-O-methyltransferase inhibitor. ...INTERPRETATION: The addition of opicapone 50 mg to levodopa treatment in patients with Parkinson's disease and end-of-dose motor fluctuations could enable a sim …
BACKGROUND: Opicapone is a novel, once-daily, potent third-generation catechol-O-methyltransferase inhibitor. ...INTERPRETATION: The …
539 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page